(Q44973266)

7 December 2017

title

GM-CSF with biochemotherapy (cisplatin, DTIC, tamoxifen, IL-2 and interferon-alpha): a phase I trial in melanoma (English)

1 reference

7 December 2017

main subject

phase I clinical trial

0 references

1 reference

1 reference

M M Vaughan

1

1 reference

7 December 2017

J Moore

2

1 reference

7 December 2017

P G Riches

3

1 reference

7 December 2017

S R Johnston

4

1 reference

7 December 2017

R P A'Hern

5

1 reference

7 December 2017

M E Hill

6

1 reference

7 December 2017

T Eisen

7

1 reference

7 December 2017

M J Ayliffe

8

1 reference

7 December 2017

J M Thomas

9

1 reference

7 December 2017

M E Gore

10

1 reference

7 December 2017

publication date

1 September 2000

1 reference

7 December 2017

1 reference

7 December 2017

volume

11

1 reference

7 December 2017

issue

9

1 reference

7 December 2017

page(s)

1183-1189

1 reference

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008348005349

7 January 2021

Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008348005349

7 January 2021

Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008348005349

7 January 2021

Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008348005349

7 January 2021

Granulocyte-macrophage colony-stimulating factor and the immune system

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008348005349

7 January 2021

Human CD14+ leukocytes acquire the phenotype and function of antigen-presenting dendritic cells when cultured in GM-CSF and IL-4.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008348005349

7 January 2021

Generation of dendritic cells from bone marrow progenitors using GM-CSF, TNF-alpha, and additional cytokines: antagonistic effects of IL-4 and IFN-gamma and selective involvement of TNF-alpha receptor-1

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008348005349

7 January 2021

GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008348005349

7 January 2021

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008348005349

7 January 2021

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008348005349

7 January 2021

Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008348005349

7 January 2021

Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1).

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008348005349

7 January 2021

Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (2).

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008348005349

7 January 2021

Clinical and immunomodulatory effects of repetitive 2-day cycles of high-dose continuous infusion IL-2.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008348005349

7 January 2021

A randomised dose escalation study of subcutaneous interleukin 2 with and without levamisole in patients with metastatic renal cell carcinoma or malignant melanoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008348005349

7 January 2021

Immunological and clinical effects of intramuscular rIFN alpha-2a and low dose subcutaneous rIL-2 in patients with advanced malignant melanoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008348005349

7 January 2021

Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008348005349

7 January 2021

Granulocyte Macrophage-Colony-Stimulating Factor (GM-CSF) Decreases CD1a Expression by Human Langerhans Cells and Increases Prolifereation in the Mixed Epidermal Cell-Lymphocyte Reaction (MELR)

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008348005349

7 January 2021

Identifiers

DOI

10.1023/A:1008348005349

1 reference

7 December 2017

1 reference